Answer
Protection from sun exposure is advised during Calquence (acalabrutinib maleate) treatment because second primary malignancies, including commonly reported skin cancers, occurred in patients with haematologic malignancies treated with Calquence alone or with other medicinal products.
Sources for this answer
- Calquence 100 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked